Exelixis Inc (EXEL) Q1 2026 Earnings Call Transcript

Why It Matters

Revenue growth and market‑share gains reinforce Exelixis’s position as a leading TKI provider, while ZANZA’s pending approval could unlock a multi‑billion‑dollar colorectal cancer opportunity and diversify future earnings.

Key Takeaways

• Cabozantinib revenue $555M, up 8% YoY
• Global cabozantinib sales $764M, +12.5% YoY
• CABOMETYX market share rose to 47% in RCC
• ZANZA NDA under FDA review, PDUFA December 2026
• $430.8M share buyback, new $50M plan authorized

Pulse Analysis

Exelixis’s Q1 performance highlights the durability of its cabozantinib franchise, the cornerstone of the company’s oncology portfolio. By delivering $555 million in U.S. cabozantinib revenue and expanding global sales to $764 million, the firm outpaced the broader oral TKI market, which grew only 7% in the same period. This growth reflects strong physician adoption of CABOMETYX in renal cell carcinoma (RCC) and neuroendocrine tumors (NETs), where it now commands a 47% market share in RCC, reinforcing its status as the leading tyrosine kinase inhibitor in these indications.

The pipeline’s next catalyst centers on ZANZA (zanzalutinib), currently under FDA review for a third‑line plus colorectal cancer indication. The STELLAR‑303 trial demonstrated a 20% reduction in mortality risk, and the upcoming PDUFA decision in December 2026 could unlock an estimated $1.5 billion U.S. market. Additional pivotal studies—STELLAR‑304 in non‑clear‑cell RCC, STELLAR‑311 in NETs, and STELLAR‑316 assessing minimal residual disease in stage II/III colorectal cancer—position ZANZA to become a multi‑indication franchise, potentially reshaping Exelixis’s revenue mix beyond the cabozantinib era.

Financially, Exelixis leverages its robust cash pile of $1.4 billion to fund R&D while returning capital to shareholders. The $430.8 million share repurchase in Q1, coupled with a fresh $50 million buyback authorization, signals confidence in the stock’s valuation and a commitment to enhancing earnings per share. Maintaining full‑year guidance amid these strategic investments suggests a balanced approach to growth and shareholder value, making Exelixis a compelling play for investors seeking exposure to innovative oncology therapeutics.